ADMA Biologics, Inc.
ADMA
$20.43
$0.592.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.34% | -1.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.34% | -1.91% | |||
| Cost of Revenue | -0.94% | -9.91% | |||
| Gross Profit | -3.53% | 6.16% | |||
| SG&A Expenses | 3.13% | 25.60% | |||
| Depreciation & Amortization | 0.00% | -10.71% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.88% | -1.22% | |||
| Operating Income | -8.98% | -3.32% | |||
| Income Before Tax | -3.64% | -5.54% | |||
| Income Tax Expenses | 108.48% | -9,288.45% | |||
| Earnings from Continuing Operations | -75.96% | 211.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -75.96% | 211.61% | |||
| EBIT | -8.98% | -3.32% | |||
| EBITDA | -8.49% | -3.15% | |||
| EPS Basic | -76.10% | 209.14% | |||
| Normalized Basic EPS | -7.47% | -2.96% | |||
| EPS Diluted | -75.95% | 204.93% | |||
| Normalized Diluted EPS | -6.56% | -2.56% | |||
| Average Basic Shares Outstanding | 0.57% | 0.79% | |||
| Average Diluted Shares Outstanding | -0.50% | 0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||